Skip Navigation



eCAM Advance Access published online on April 20, 2005
eCAM, doi:10.1093/ecam/neh086
This Article
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
2/2/223    most recent
neh086v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Tsukamoto, S.
Right arrow Articles by Ohta, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsukamoto, S.
Right arrow Articles by Ohta, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press. All rights reserved.
Received September 30, 2004
Revised January 18, 2005
Accepted March 28, 2005

Brief Communication

Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa)

Sachiko Tsukamoto 1, Maki Aburatani 1, and Tomihisa Ohta 1*

1 Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

* To whom correspondence should be addressed.
Tomihisa Ohta, E-mail: ohta{at}p.kanazawa-u.ac.jp


  Abstract

Recent investigation on drug interaction has shown that some foods and herbal medicines increase the oral availability of a variety of CYP3A4 substrates, which is caused by the reduction of CYP3A4 in intestinal epithelium. During the course of our investigation on CYP3A4 interaction, we found that the commercially available dietary supplement made from black cohosh (Cimicifuga racemosa) showed CYP3A4 inhibition. Black cohosh has been used for the treatment of menopausal and post-menopausal symptoms as a dietary supplement. Bioassay-guided isolation from the supplement afforded six active principles, which were identified as cycloartanoid triterpene glycosides.

Keywords: black cohosh; Cimicifuga racemosa; CYP3A4; cytochrome P450; inhibition; triterpene glycoside.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
N. M. Patel and R. M. Derkits
Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration
Journal of Pharmacy Practice, August 1, 2007; 20(4): 341 - 346.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
B. Gurley, M. A. Hubbard, D. K. Williams, J. Thaden, Y. Tong, W. B. Gentry, P. Breen, D. J. Carrier, and S. Cheboyina
Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin
J. Clin. Pharmacol., February 1, 2006; 46(2): 201 - 213.
[Abstract] [Full Text] [PDF]

E-letters:

Read all E-letters

No characterisation of the extract and questionable in-vivo correlation.
Beat Meier, et al.
Evidence-based Complementary and Alternative Medicine, 12 Aug 2005 [Full text]

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.